SUBSCRIBE BACK TO RESULTS Bioventus’ Shareholders Approve Acquisition of Misonix Mon, 11/01/2021 - 12:00 | Christopher L. Lewis Medical Devices & Procedures Bioventus recently announced that its shareholders approved its agreement to acquire Misonix. Bioventus agrees to pay Misonix shareholders either 1.6839 shares of Bioventus class A common stock or $28.00 for each share of Misonix common stock held. The amount paid to Misonix shareholders results in an approximate valuation of $518 million for Misonix, based on share prices from around the time the acquisition agreement was reached. With the completion of this acquisition, Misonix will become a wholly-owned subsidiary of Bioventus. Misonix develops minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products for a variety of orthopedic applications. For example, Misonix is the developer of the BoneScalpel, an ultrasonic bone cutting tool. Additionally, Misonix is the developer of the Nexus, an ultrasonic surgical aspirator for precision hard and soft tissue removal. In a press release, Bioventus’ CEO Ken Reali stated: Bioventus plans to accelerate the adoption of Misonix’s BoneScalpel and Nexus products through the footprint of Bioventus in the spine surgical solutions area. Bioventus also plans to augment its current lower extremity product offerings with Misonix’s products. This acquisition is one of three acquisitions by Bioventus this year. Earlier this year, Bioventus acquired Bioness, the developer of neuromodulation and rehabilitation medical devices. Bioventus also has an agreement in place to acquire CertiHeal, the developer of the Agili-C implant. Christopher L. Lewis Christopher L. Lewis’s practice focuses on representing clients in intellectual property disputes involving patents, trademarks, and trade secrets. He has... Copyright © 2021 Knobbe Martens All Rights Reserved Footer CONTACT US MEDIA & PRESS SUBSCRIBE PRIVACY & COOKIE POLICY TERMS & CONDITIONS | LEGAL DISCLAIMER | ATTORNEY ADVERTISING x This website uses cookies to provide you with the best user experience. If you choose not to accept the use of cookies, we cannot guarantee an optimized experience, including access to certain video content. For more information about how we use cookies, please see our Privacy & Cookie Policy Accept